Applications:The present invention covers the use of quaternary compounds with antimuscarinic (anticholinergic) properties for the treatment of bladder diseases, including urinary incontinence. The present compounds extend the existing patent portfolio to embrace a family of structures that show promise for intravesical use. The preferred rout of administration is intravesical. Oral or systemic routes might be effective if controlled release within the bladder could be achieved with further pharmaceutical development effort.Advantages:The present compounds have high affinity for muscarinic receptors and as a result extend the half-times in receptor binding. Intravesical administration via catheterization will provide for long-term bladder control while limiting systemic absorption and the deleterious side effects of antimuscarinic agents in use currently. In addition, the bladder itself may act as a storage compartment for these agents because of the quaternary state of the compounds and the fact that the urothelium is lined glycosaminoglycans carrying an opposing charge.